Multiple Myeloma Research Foundation (MMRF) and Sunesis Pharmaceuticals, Inc. Present Data On SNS-032 At American Association for Cancer Research Annual Meeting

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Consortium (MMRC) in collaboration with Sunesis Pharmaceuticals presented preclinical data on the activity of Sunesis’ cell cycle inhibitor, SNS-032, in multiple myeloma cell assays and animal models. The data was presented orally at the 2008 Annual Meeting of the American Association of Cancer Research.

MORE ON THIS TOPIC